Stealth’s Flight Path Returns to FDA for Rejected Barth Drug
Stealth BioTherapeutics originally submitted elamipretide for approval in January 2024, only to receive a rejection in May of this year. In addition to accepting the biotech’s resubmission, the FDA has promised to take action on the candidate by Sept. 26.
Stealth’s Flight Path Returns to FDA for Rejected Barth Drug Read More »
